primary%20biliary%20cholangitis
PRIMARY BILIARY CHOLANGITIS

Primary biliary cholangitis (formerly primary biliary cirrhosis) is a chronic, progressive, autoimmune, cholestatic liver disease more common in middle-aged women. It is characterized by destruction of small to medium bile ducts leading to cholestasis and frequently, end-stage liver disease.
Diagnostic features are chronic biochemical cholestasis, presence of antimitochondrial antibodies and the characteristic liver biopsy findings.


 

  1. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000 Apr;31(4):1005-1013. PMID: 10733559
  2. Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst Rev. 2004 Feb:CD004481. PMID: 15106254
  3. Pratt DS. Cholestasis and cholestatic syndromes. Curr Opin Gastroenterol. 2005 May;21(3):270-274. PMID: 15818146
  4. Oo YH, Neuberger J. Options for the treatment of primary biliary cirrhosis. Drugs. 2004;64(20):2261-2271. PMID: 15456326
  5. Prince M, Christensen E, Gluud C. Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database Syst Rev. 2005 Apr;(2):CD003778. PMID: 15846681
  6. Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology/diagnosis/management. 7th ed. Pennsylvania: Saunders; 2002
  7. MedWormhttp://www.medworm.com/rss/index.php/Gastroenterology/17/http://www.medworm.com/rss/medicalfeeds/specialities/Gastroenterology.xml
  8. Pyrsopoulos NT, Rajernder Reddy K. Primary biliary cirrhosis. http://emedicine.medscape.com. Sep 2004. Accessed 12 Sep 2005.
  9. Poupon R. Overview of the treatment of primary biliary cirrhosis. UpToDate. http://www.uptodate.com. 16 Jul 2013. Accessed 13 Mar 2014.
  10. Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis. Hepatology Research. 2014;44(Suppl 1):71–90. doi: 10.1111/hepr.12270. Accessed 12 Mar 2014
  11. Civan JM. Cirrhosis. The Merck Manual. http://www.merckmanuals.com. Jul 2013.
  12. Purohit T, Cappell MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol. 2015 May 8;7(7):926-941. doi: 10.4254/wjh.v7.i7.926. PMID: 25954476
  13. European Association for the Study of the Liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017 Jul;67(1):145-172. doi: 10.1016/j.jhep.2017.03.022. PMID: 28427765
  14. Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019 Jan;69(1):394-419. doi: 10.1002/hep.30145. PMID: 30070375
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, Yesterday

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Stephen Padilla, 4 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.